Regenacy Pharmaceuticals is a pioneering brand that specializes in developing innovative treatments through the regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme (HDAC) inhibitors. They focus on restoring nerve function to treat peripheral neuropathies, with a particular emphasis on diabetic peripheral neuropathy. Their lead compound, ricolinostat (ACY-1215), is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6, with first-in-class potential.

They are entering a proof-of-concept Phase 2 clinical trial using ricolinostat for diabetic peripheral neuropathy. Regenacy Pharmaceuticals was founded in December 2016 and acquired exclusive rights to ricolinostat from Acetylon Pharmaceuticals. Additionally, they have a unique portfolio of selective HDAC1,2 inhibitors that have potential applications in treating cancer, hemoglobinopathies, and cognitive dysfunction.

With a dedicated team and a focus on disease-modifying approaches, Regenacy Pharmaceuticals is dedicated to improving the lives of those with peripheral neuropathies